Mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma

Lancet Oncol. 2022 Aug;23(8):967-969. doi: 10.1016/S1470-2045(22)00385-0. Epub 2022 Jul 5.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Bispecific* / adverse effects
  • Antineoplastic Agents* / therapeutic use
  • Humans
  • Lymphoma, Follicular* / pathology

Substances

  • Antibodies, Bispecific
  • Antineoplastic Agents